Sugar swap showdown: erythritol vs. sucrose in teens

NCT ID NCT04966299

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This pilot study compares the effects of daily erythritol (a sugar substitute) versus regular sugar on insulin resistance and blood clotting in 30 healthy adolescents aged 14-18. Participants consume either erythritol or sucrose for 5 weeks, and researchers measure changes in glucose tolerance, body composition, and platelet function. The goal is to understand if erythritol is a safer alternative to sugar for teens.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2021

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

14 to 55 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

EryAdo: Inclusion Criteria: * Healthy adolescents * Aged 14-18 years * Normal weight (BMI between 15th and 85th percentile for age and gender) * Minimum weight of 45kg * Regular sugar consumption \>25g/d Exclusion Criteria: * Severe acute or chronic diseases * Pregnancy * Regular intake of prebiotics * Regular intake of probiotics * Regular intake of pro-/prebiotic foods * Antibiotics cure within 3 months preceding the present study * Substance abuse * Inability to follow procedures due to psychological disorders or insufficient knowledge of project language (German) * Participation in another study with investigational drug within the 30 days preceding and during the present study. * Pre-existing regular consumption (\>1/week) of erythritol * Fructose-intolerance * Pre-existing diet (vegetarian, vegan, gluten-free, lactose-free, caloric restriction, etc.) EryClot-Pilot: 3 participants Inclusion criteria: * Healthy participants 18-55 years upon inclusion * Normal weight (BMI between 19.0-24.9 kg/m2) * Informed consent signed by participant Exclusion criteria: * Severe acute or chronic diseases * Pregnancy: although no contraindication, pregnancy might influence metabolic state. Female adolescents who are pregnant or have the intention to become pregnant during the course of the study are excluded. In female participants a urine pregnancy test is carried out upon screening * Substance abuse, smoking * Inability to follow procedures due to psychological disorders or insufficient knowledge of project language (German) * Participation in another study with investigational drug within the 30 days preceding and during the present study. * Pre-existing regular consumption (\>1/week) of erythritol * Fructose-intolerance EryClot: Inclusion criteria: * Healthy participants 18-55 years upon inclusion * Normal weight (BMI between 19.0-24.9 kg/m2) * Informed consent signed by participant, Exclusion criteria: * Severe acute or chronic diseases * Pregnancy: although no contraindication, pregnancy might influence metabolic state. Female adolescents who are pregnant or have the intention to become pregnant during the course of the study are excluded. In female participants a urine pregnancy test is carried out upon screening * Substance abuse, smoking * Inability to follow procedures due to psychological disorders or insufficient knowledge of project language (German) * Participation in another study with investigational drug within the 30 days preceding and during the present study. * Pre-existing regular consumption (\>1/week) of erythritol or xylitol * Pre-existing impairment of blood coagulation/thrombocyte function (e.g., hereditary, regular intake of anti-coagulant agents (e.g., NSAIDs, heparin, warfarin, etc.)) EryClot in vitro Inclusion criteria: * Healthy participants 18-55 years upon inclusion * BMI \< 30 kg/m2 * Informed consent signed by participant Exclusion criteria: * Severe acute or chronic diseases * Pregnancy: although no contraindication, pregnancy might influence metabolic state. Female adolescents who are pregnant or have the intention to become pregnant during the course of the study are excluded. * Substance abuse, smoking * Inability to follow procedures due to psychological disorders * Participation in another study with investigational drug within the 30 days preceding and during the present study. * Pre-existing regular consumption (\>1/week) of erythritol or xylitol * Pre-existing impairment of blood coagulation/thrombocyte function (e.g., hereditary, regular intake of anti-coagulant agents (e.g., NSAIDs, heparin, warfarin, etc.))

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Blood erythritol are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glucose intolerance Insulin Resistance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • St. Claraspital

    Basel, Canton of Basel-City, 4002, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.